Phathom Pharmaceuticals, Inc. PHAT
5.74 USD -0.17 (-2.96%)
At closeNov 3, 2026, 4:06 PM EST
5.74 0.00 0.00%
After hours · Nov 3, 4:06 PM ET
5.50 Day range 6.11
5.02 52-week range 18.31
- YTD
- -65.40%
- 1 year
- -58.19%
Financial health
Altman Z-Score
-4.79 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -5.5×
FY 2018 5y median -2.3× FY 2025
P/S 6.9×
FY 2018 5y median 6.9× FY 2025
P/B -2.8×
FY 2018 5y median -2.8× FY 2025
P/FCF -7.3×
FY 2018 5y median -3.4× FY 2025
EV/EBITDA -8.5×
FY 2018 5y median -2.2× FY 2025
EV/Sales 7.4×
FY 2018 5y median 7.4× FY 2025
FCF Yield -13.8%
FY 2018 5y median -29.7% FY 2025
Profitability
Gross Margin 87.1%
FY 2018 5y median 75.5% FY 2025
Operating Margin -91.4%
FY 2018 5y median -91.4% FY 2025
Net Margin -126.3%
FY 2018 5y median -126.3% FY 2025
ROE 50.5%
FY 2018 5y median 131.8% FY 2025
ROIC -125.2%
FY 2018 5y median -94.7% FY 2025
ROA -85.4%
FY 2018 5y median -85.4% FY 2025
Growth (YoY)
Revenue 216.9%
FY 2018 FY 2025
Operating Income 42.3%
FY 2018 FY 2025
EPS (diluted) 42.7%
FY 2018 FY 2025
Free Cash Flow 37.5%
FY 2018 FY 2025
Financial Health
Current Ratio 1.7×
FY 2018 5y median 6.1× FY 2025
Quick Ratio 1.7×
FY 2018 5y median 6.1× FY 2025
Debt / Equity -0.5×
FY 2018 5y median -0.8× FY 2025
Net Debt / EBITDA -0.5×
FY 2018 5y median 0.4× FY 2025
Interest Coverage -2.3×
FY 2018 5y median -4.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31